BRAF<sup>V600E</sup> Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Opening Hours
Collections
Help Via Email

Electronic Information Resources

BRAF^V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

详细信息查看全文

作者：Kristel Kemper¹ ; ⁹ ; Oscar Krijgsman¹ ; ⁹ ; Xiangjun Kong¹ ; Paulien Cornelissen-Steijger¹ ; Aida Shahrabi¹ ; Fleur Weeber¹ ; Daphne L. van der Velden¹ ; Onno B. Bleijerveld² ; Thomas Kuilman¹ ; Roel J.C. Kluin³ ; Chong Sun⁴ ; Emile E. Voest¹ ; Young Seok Ju⁵ ; Ton N.M. Schumacher⁶ ; A.F. Maarten Altelaar² ; ⁷ ; Ultan McDermott⁵ ; David J. Adams⁸ ; Christian U. Blank⁶ ; John B. Haanen⁶ ; Daniel S. Peeper¹ ; ^{d.peeper@nki.nl" class="auth_mail" title="E-mail the corresponding author}
刊名：Cell Reports
出版年：2016
出版时间：28 June 2016
年：2016
卷：16
期：1
页码：263-277
全文大小：5933 K

文摘

titem" id="list_ulist0010">t class="label">•t>

Patient-derived xenograft (PDX) platform comprises 89 metastatic melanoma tumors

t class="label">•t>

Platform includes several pre-vemurafenib and vemurafenib-resistant PDXs

t class="label">•t>

Duplication of the BRAF^V600E kinase domain is identified as a resistance mechanism

t class="label">•t>

Pan-RAF dimerization inhibitor LY3009120 eliminates melanoma cells with this duplication

NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.